Laurence Capron
Author's details
Name: Laurence Capron
Date registered: May 3, 2012
URL: http://www.insead.edu/facultyresearch/faculty/personal/lcapron/
Biography
Laurence Capron is the Paul Desmarais Chaired Professor of Partnership and Active Ownership at INSEAD and Director of INSEAD Executive Education Programme on “M&As and Corporate Strategy”. Her teaching and research activities focus on M&As, Alliances, Corporate Development and Business Portfolio Strategy. She teaches in MBA, Executive MBA, Executive Education and Ph.D programmes.
Professor Capron has received teaching awards, including the INSEAD Best Teaching Award for her MBA elective on “M&As and Corporate Strategy”, which she has taught at INSEAD and Wharton. She is also the recipient of multiple research awards, including Academy of Management Best Paper Award, McKinsey-Strategic Management Society Best Paper Award, HEC Paris Foundation Best Doctoral Dissertation Award and Syntec Award for Best Research in Management. Her current research agenda focuses on how companies select and use M&As in their corporate development and combine organic growth with their acquisitive growth.
Professor Capron joined INSEAD in 1997 after earning her Ph.D in Strategy from HEC Paris. She was Visiting Associate Professor of Strategy at Wharton (2005-06) and Visiting Scholar at Kellogg (2004-05) and Michigan (1993-94). She directed the INSEAD-Wharton Alliance from 2007-2010. She sits on the Editorial Board of the Strategic Management Journal, the leading academic journal in the field of strategy.
Latest posts
- Warning Against Binge Buying. When is M&A the Right Answer to Your Growth Challenges? — December 17, 2012
- Why Chinese Firms’ Cross-Border Deals Fall Apart — November 22, 2012
- Yahoo’s challenge: Finding a viable growth path via acquisitions — October 30, 2012
- Why Apple Made the Right Call on Apple Maps — October 8, 2012
- The Company Outsmarting Big Pharma in Africa — August 20, 2012
Author's posts listings
By Laurence Capron & Will Mitchell
One of the truisms of business life is that mergers and acquisitions often create more headlines than value. Some studies indicate that 70% of deals fail to achieve their objectives. In our research on 150 ICT firms (“Build, Borrow or Buy: Solving the Growth Dilemma”, Harvard Business Review Press… Read more, 2012), only 27% of the responding firms reported they were able to extract the value that they wanted to achieve from their target firms’ capabilities following their acquisitions.
Permanent link to this article: http://blog.insead.edu/2012/12/warning-against-binge-buying-when-is-ma-the-right-answer-to-your-growth-challenges/
By Laurence Capron & Will Mitchell
During the past decade, Chinese firms have become aggressive cross-border acquirers. Unfortunately they have been struggling to actually close their deals.
Some deals have failed because of national security concerns in the U.S., including CNOOC’s attempt to purchase Unocal in 2005 and Huawei’s attempt to buy 3Leaf Systems in 2011.… Read more
Permanent link to this article: http://blog.insead.edu/2012/11/why-chinese-firms-cross-border-deals-fall-apart/
Yahoo CEO Marissa Mayer recently announced her plan to make acquisitions to revitalize and grow Yahoo. Her announcement generated a lot of reaction, but not so much about her ability to execute M&As — Mayer brings M&A experience gained at Google, and if she sticks with relatively small, educational acquisitions, failure on one deal will not break the company.… Read more
Permanent link to this article: http://blog.insead.edu/2012/10/yahoos-challenge-finding-a-viable-growth-path-via-acquisitions/
By Laurence Capron and Will Mitchell
Though it has been widely available for only a few days, mounting complaints over Apple’s new mapping application, seen as a poor substitute for the Google Maps application that it replaces, are tarnishing the launch of the iPhone5.… Read more
Permanent link to this article: http://blog.insead.edu/2012/10/why-apple-made-the-right-call-on-apple-maps/
By Laurence Capron & Will Mitchell
Cipla, an India-based producer of low cost antiretroviral drugs (ARVs) is one of the biggest success stories in the pharma industry. Most of its sales are in the developing world (including 40% in Africa) — where it sells its HIV drugs for about $350 per year per patient — yet it is as profitable as the pharma giants of Europe, North America, and Japan.… Read more
Permanent link to this article: http://blog.insead.edu/2012/08/the-company-outsmarting-big-pharma-in-africa/
By Laurence Capron and Will Mitchell
Historically, big pharma firms made their own drugs. They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves.… Read more
Permanent link to this article: http://blog.insead.edu/2012/08/big-pharmas-mixed-modes-of-growth/
By Laurence Capron & Will Mitchell
Companies tend to repeat what has worked for them in the past. In our research on the telecom industry, for example, we found that the great majority of the executives we surveyed preferred internal development to external sourcing when they needed to develop differentiated products and services.… Read more
Permanent link to this article: http://blog.insead.edu/2012/07/when-to-change-a-winning-strategy/
There is something broken in the way many businesses obtain the resources necessary for growth. Most companies are very good at identifying what those new resources are, and nearly all of them take that challenge seriously. Yet, we have seen company after company– even highly regarded ones — get into trouble as they grow because they pay much less attention to choosing the right way to obtain resources than to the task of identifying them. … Read more
Permanent link to this article: http://blog.insead.edu/2012/05/the-corporate-growth-dilemma-build-borrow-or-buy/
